抗病毒治疗对HBV DNA阳性乙型肝炎肝硬化门脉高压症患者术后临床转归的影响*

doi:10.3969/j.issn.1672-5069.2015.05.007

Abstract

Abstract: Objective To explore the effect of antiviral therapy on the clinical postoperative prognosis of patients with serum HBV DNA-positive hepatitis B related cirrhosis and portal hypertension（PH）. Methods 89 patients with serum HBV DNA positive liver cirrhosis and PH were randomly divided into intervention group（n=49） receiving selected splenectomy and entecavir，and control group（n=41） receiving selected splenectomy alone. The liver function tests，serum HBV DNA levels，Child-Pugh scores，liver fibrosis markers were routinely obtained， and the survival rates were observed. Results At the end of 1 month and 3 month after surgery，the serum HBV DNA levels in intervention group were （5.79±1.78） lgcopies/L and （4.24±1.61） lgcopies/L，respectively，while it didn’t change in the control group （P<0.01）；The serum alanine aminotransferase and total bilirubin levels in intervention group decreased，albumin increased as compared to those in control（P<0.01）；the survival rates at 1 a and 3 a in invention group were 93.7% and 75.0%，much higher than 87.9% and 68.3%，in the control （P＜0.05）. Conclusions Antiviral therapy after selected splenectomy in PH patients with positive HBV DNA can promote the 1iver function recovery and better clinical prognosis.

Key words: Liver cirrhosis, Portal hypertension, Entecavir, Survival rates

Yu Jihai，Xu Geliang，Li Jiansheng，et al.. Influence of antiviral therapy on the clinical postoperative prognosis of patients with serum HBV DNA-positive hepatitis B related liver cirrhosis and portal hypertension[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(5): 472-475.

References

[1] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志，2011，14（2）：81-89.
[2] 殷照才，许戈良，荚卫东. 选择性断流术治疗门静脉高压症的研究进展. 中华外科杂志，2010，48（4）：305-307.
[3] 杨镇.选择性贲门周围血管离断术的解剖学命名和操作步骤 .外科理论与实践，2009，14（1）：188-191．
[4] 鲁晓擘，沙尼亚尼亚孜，甄作睿，等. 长期抗病毒治疗对乙型肝炎肝硬化患者预后及转归的影响. 肝脏，2013，18（9）：591-595．
[5] 李磊，刘伟，陈玉涵，等. 不同核苷类似物抗病毒治疗方案治疗失代偿期乙肝肝硬化的临床研究.北京医学，2014，36（12）：1017-1021．
[6] 杨静，伍锡刚，张杰. 恩替卡韦联合保肝药物治疗肝硬化失代偿期患者的疗效分析. 临床医学与检验，2014，11（24）：3443-3444．
[7] 杨建新，燕青松. 阿德福韦酯联合拉米夫定治疗乙肝肝硬化失代偿者中远期临床疗效观察. 临床军医杂志，2013，41（5）：528-530．
[8] Chen G，Lin W，Shen F，et al. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study．Am J Gastroenterol，2006，101（8）：1797-1803．
[9] 徐启桓，陈禄彪，许镇，等. 抗病毒治疗对乙型肝炎相关慢加急性肝衰竭患者短期生存率的影响.中华实验和临床病毒学杂志，2009，23:467-469.
[10] 肖光明，贾卫东，何凯茵，等. 应用Cox比例风险模型分析抗病毒治疗对慢性乙型重型肝炎预后的影响. 实用肝脏病杂志，2009，12（3）:190-194.
[11] Leung N，Peng CY，Hann HW，el a1．Early hepatitis B virus DNA reduction in hepatitis B e antigen positive patients with chronic hepatitis B：A randomized international study of entecavir versus adefovir．Hepatology，2009，49（1）：72-79．
[12] 王正峰，周光文. 中国4250例门静脉高压症手术的Meta分析.中华普通外科杂志，2012，27（8）：643-649.
[13] 刘文娜，郝婷婷，王剑，等. 64层螺旋CT门静脉造影对肝硬化患者肝功能分级和食管静脉曲张破裂出血的预测价值.实用肝脏病杂志，2014，17（3）：283-286.
[14] 程小飞，梁雄波，熊晓红，等. 超声多普勒测定肝硬化患者门脉系统参数与Fibroscan 得分的相关性分析.实用肝脏病杂志，2014，5(17）：283-286.
[15] Chang TT，Liaw YF，Wu SS，et a1． Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B． Hepatology，2010，52（3）：886-893．
[16] 许蓓，徐国光，郭清，等. 拉米夫定对慢性乙型肝炎伴重度肝纤维化患者的长期应用疗效－NUCB4006十年随访研究.中华传染病杂志，2010，28（11）:656-661.
[17] 冯玉奎，郑长青. 血清肝纤维化检测在诊断肝纤维化中的临床应用. 肝脏，2011，16（2）：171-172.
[18] Pozzi M，Pizzala DP，Maldini FF，et al. Portal pressure reduction after entecavir treatment in compensated HBV cirrhosis. Hepatogastroenterology，2009，56（89）:231-235.
[19] Sherman M，Yurdaydin C，Sollano J，et al. Entecavir for treatment of lamivudine-refractory，HBeAg-positive chronic hepatitis B.Gastroenterology，2006，130（7）:2039-2049.
[20] Wang LC，Chen EQ，Cao J，et al. De novo combination of lamivudine and adefovir versus entecavir monotherapy for the treatment of negative HBeAg-negative chronic hepatitis B patients. Hepatol Int，2011，5（2）:671-676.

Influence of antiviral therapy on the clinical postoperative prognosis of patients with serum HBV DNA-positive hepatitis B related liver cirrhosis and portal hypertension

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhuang Ying, Lin Zhihui.. Clinical manifestations and diagnosis of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 765-767.
[2]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[3]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[4]	He Zhi’an, Yu Liping, Lai Jiangqiong, et al.. Evaluation of varices bleeding and portal vein thrombosis by ARFI in patients with cirrhosis and esophagogastric varices [J]. Journal of Practical Hepatology, 2019, 22(6): 888-891.
[5]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[6]	Zhang Rui, Wang Jian, Chen Shiyao.. Mechanism of portal vein thrombosis in cirrhotic patients with portal hypertension and the treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 930-933.
[7]	Wang Yueyuan, Wang Yan, Zhang Dandan. Short-term efficacy of terlipressin and octreotide combination in treatment of cirrhotic patients complicated by hepatorenal syndrome [J]. Journal of Practical Hepatology, 2019, 22(5): 684-687.
[8]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[9]	Dan Zhuyongji, Liu Zhilan, Lu Yanyan, et al. Efficacy of endoscopic sequential variceal 1igation plus sclerotherapy in treatment of patients with hepatitis B-induced liver cirrhosis complicated by esophageal gastric varices bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 692-695.
[10]	Huang Hanjun, Lu Fengrong, Zhang Can. Clinical value of MRI scanning based on exchange hemodynamics model in evaluating liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 696-699.
[11]	Zhao Fangfang, Zhai Yongzhen, Feng Guohe. Efficacy and safety of autologous peripheral blood stem cell transplantation in patients with hepatitis B cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 700-703.
[12]	Chen Shan, Zhuang Huashuai, Xing Yixi, et al. Preventive application of meropenem in patients with liver cirrhosis complicated by upper gastrointestinal bleeding [J]. Journal of Practical Hepatology, 2019, 22(5): 704-707.
[13]	Xu Qilin, Hao Shaohuan, Ran Bo. Risk factors of portal vein thrombosis after splenectomy in patients with liver cirrhosis and portal hypertension [J]. Journal of Practical Hepatology, 2019, 22(5): 708-711.
[14]	Jin Lianghong, Li Xingjie, Guan Hongbo, et al. Clinical value of dual-energy CT iodine quantification combined with dynamic contrast-enhanced MRI in evaluating hepatic hemodynamics and liver functions in patients with hepatitis B liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(5): 712-715.
[15]	Bian Xinqu, Chen Jie, Liu Yanmin, et al. Serum thyroid hormone level changes in patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy [J]. Journal of Practical Hepatology, 2019, 22(5): 716-719.